Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (ATXS)
NASDAQ:ATXS
Total Valuation
Astria Therapeutics has a market cap or net worth of $719.27M. The enterprise value is $294.35M.
Market Cap$719.27M
Enterprise Value$294.35M
Share Statistics
Astria Therapeutics has 57,084,840 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,084,840
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Astria Therapeutics’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -34.22%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-34.22%
Return on Capital Employed (ROCE)-0.35
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count78
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Astria Therapeutics is ―. Astria Therapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio0.00
PB Ratio1.57
Price to Fair Value1.57
Price to FCF-6.16
Price to Operating Cash Flow-6.25
PEG Ratio0.17
Income Statement
In the last 12 months, Astria Therapeutics had revenue of 0.00 and earned -94.26M in profits. Earnings per share was -1.68.
Revenue0.00
Gross Profit0.00
Operating Income-111.56M
Pretax Income-94.26M
Net Income-94.26M
EBITDA-111.56M
Earnings Per Share (EPS)-1.68
Cash Flow
In the last 12 months, operating cash flow was -119.73M and capital expenditures -590.00K, giving a free cash flow of -120.32M billion.
Operating Cash Flow-119.73M
Free Cash Flow-120.32M
Free Cash Flow per Share-2.11
Dividends & Yields
Astria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.76
52-Week Price Change29.09%
50-Day Moving Average11.10
200-Day Moving Average7.18
Relative Strength Index (RSI)73.76
Average Volume (3m)1.09M
Important Dates
Astria Therapeutics upcoming earnings date is Mar 5, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 5, 2026
Ex-Dividend Date―
Financial Position
Astria Therapeutics as a current ratio of 17.49, with Debt / Equity ratio of 1.83%
Current Ratio17.49
Quick Ratio17.49
Debt to Market Cap<0.01
Net Debt to EBITDA0.58
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Astria Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Astria Therapeutics EV to EBITDA ratio is -4.75, with an EV/FCF ratio of -5.49.
EV to Sales0.00
EV to EBITDA-4.75
EV to Free Cash Flow-5.49
EV to Operating Cash Flow-5.51
Balance Sheet
Astria Therapeutics has $227.72M in cash and marketable securities with $4.46M in debt, giving a net cash position of $223.26M billion.
Cash & Marketable Securities$227.72M
Total Debt$4.46M
Net Cash$223.26M
Net Cash Per Share$3.91
Tangible Book Value Per Share$5.68
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Astria Therapeutics is $20.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$20.00
Price Target Upside52.79% Upside
Analyst ConsensusHold
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-2.74%